prospective longitudinal assessment of cardiovascular toxicity of childhood cancer treatment

prospective longitudinal assessment of cardiovascular toxicity of childhood cancer treatment - CLEP2

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32995

Enrollment

225

Registered

2009-10-12

Start date

2010-01-22

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac dysfunction decreased heartfunction

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: newly diagnosed childhood cancer patients age 0-18 years written informed consent

Exclusion criteria

Exclusion criteria: inadequate knowledge of the dutch language for reading the information and writing informed consent

Design outcomes

Primary

Measure	Time frame
1. Prevalence of subclinical cardiac damage (diagnosed by echocardiography as either systolic, diastolic or combined dysfunction) 2. Prevalence of cardiovascular risk factors (blood pressure, vascular wall changes, body composition and metabolic syndrome) 3. Changes in intima media thickness in carotid-/femoral arteries after treatment with anthracyclines and/or thoracal/neckradiation.	—

Countries

Netherlands

Outcome results